OMIX_【About us】

Our Mission

To drive industry innovation through technology, pioneering global leadership in AI + Healthcare, and creating sustainable value for human health and well-being.

Our Vision

To become the globally leading architect of AI-driven health ecosystems.

Our Core Values

Innovate Collaborate Seek Knowledge Uphold Responsibility.

About us

OMIX SCIENCE is an AI-driven medical company founded by a team of Harvard Ph.D. graduates. The company integrates world-leading technologies across artificial intelligence (AI), synthetic biotechnology (BT), medical technology (MT), and information technology (IT), focusing on two strategic areas: early detection of complex diseases and aging intervention.

Leveraging internationally competitive R&D capabilities, the company is deeply engaged across three golden sectors: biopharmaceuticals, information technology, and the silver economy. Committed to spearheading industry transformation, the company is building a globally influential innovation cluster centered on "AI + Early Disease Detection + Aging and Aging-Related Diseases Intervention", establishing a new paradigm of synergistic industrial development.

Platform Expansion

50+

Private Institutions

Personalized Health Checkup Services

Win-win Sharing

Multiple Cooperation Models

30+

Grade 3A hospitals

Deep Clinical Trial Cooperation

Jointly Developing Innovative Product Lines

Sharing Premium Resources

Medical Testing Laboratories

Standardized, Normalized, Precise Processes

Advanced Laboratory Technology

Mature Management Experience

R&D Centers/ Research and Development Centers

BT+MT+IT+AI

Fundamental Research Platform

Team of World-class Experts

Core Team

Qualifications and Honors

Awarded Shenzhen "Seed Unicorn" in 2025
Completed pre-A round financing of ¥30M in July 2024, led by experienced and reputable investment institutions in the industry
Global 2nd place at 2025 Harvard College China Forum as the only virtually attended team among 100+ competitors from world’s top institutions, such as Harvard, MIT, Stanford, etc. （physical attendance required for global 1st place）
Won the Second Prize at the 6th "China Merchants Cup" Innovation & Entrepreneurship Competition — hosted by China Merchants Group with strong support from the NDRC,MOST, SASAC,CAST. As the only independently participating enterprise in the healthcare sector,OMIX emerged as a standout winner among over 600 competing companies led by academicians or renowned experts nationwide
Won the first prize of “2023 Tumor Marker Innovative Technology Product” awarded by the Chinese Anti-Cancer Association
Invited to participate in the formulation and drafting of the national-level major task “White Paper on National Tumor Molecular Diagnostic Technology Industry” (led by China Association for Science and Technology, Chinese Anti-Cancer Association, Chinese Medical Association, and China Tumor Marker Association)
Invited to participate in the formulation of China’s first pan-cancer joint screening guidelines led by the National Cancer Center affiliated with the National Health Commission
First batch of pilot units for the Cancer Prevention and Control Project of the Healthy China Action and a member of the Health Work Committee of the China Anti-Aging Association
Has undertaken two major projects in Zhejiang Province – “Jian Bing” “Ling Yan” R&D projects - development of new technologies and products for early screening and diagnosis of malignant tumors
Selected into the “Digital Medical Products and Services High-Quality Development Panorama" published by China Academy of Information and Communications Technology(CAICT)
In addition, OMIX has been honored with a series of prestigious awards, such as two awards in the 2024 National Medical Artificial Intelligence Competition, the "Golden Screening Award" for "Leading Enterprise" in the Early Screening Industr at the World Conference on Early Cancer Screening, and dual awards for "Technological Innovation" and "Transformation of scientific and technological achievements" at the Fourth Genetic Technology Forum simultaneously